{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:55:12Z","timestamp":1781762112745,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease is a rare X-linked hereditary lysosomal storage disorder. Its cardiac manifestations often overlap with those of hypertrophic cardiomyopathy or coronary artery disease, leading to significant delays in diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>\n                      A 60-year-old male patient presented with exertional angina pectoris, which had persisted for 15 years. Initially diagnosed with coronary artery disease, he underwent percutaneous coronary intervention. Despite successful revascularization, he subsequently developed progressive left ventricular hypertrophy, heart failure, bilateral hearing loss, dizziness, and white matter lesions in the brain. Cardiac magnetic resonance imaging revealed mid-myocardial striae-like late gadolinium enhancement and left ventricular high voltage on electrocardiography, raising a strong suspicion of Fabry disease. Plasma \u03b1-galactosidase A activity was significantly decreased (0.62 \u03bcmol\/L), and genetic testing identified a hemizygous pathogenic variant in the\n                      <jats:italic>GLA<\/jats:italic>\n                      gene [c.718_719del (p.K240fs)], confirming the diagnosis of Fabry disease. Due to various reasons, enzyme replacement therapy was not initiated, and the patient is currently managed with a heart failure and secondary prevention regimen for coronary artery disease, with stable disease status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights the challenges in identifying Fabry disease in patients with coexisting coronary artery disease and left ventricular hypertrophy. It emphasizes the diagnostic value of multi-system involvement and characteristic imaging findings. A diagnostic pathway incorporating clinical warning signs, cardiac magnetic resonance imaging, enzymatic assays, and genetic testing can help reduce diagnostic delays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1846913","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:26Z","timestamp":1781760626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Fabry disease mimicking coronary artery disease and hypertrophic cardiomyopathy\u2014a 15-year diagnostic delay"],"prefix":"10.3389","volume":"13","author":[{"given":"Tielang","family":"Liang","sequence":"first","affiliation":[{"name":"Cardiology Department, The Eighth Affiliated Hospital of Guangxi Medical University","place":["Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Cardiology Department, The Eighth Affiliated Hospital of Guangxi Medical University","place":["Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Huang","sequence":"additional","affiliation":[{"name":"Cardiology Department, The Eighth Affiliated Hospital of Guangxi Medical University","place":["Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.20452\/pamw.15117","article-title":"Enzyme replacement therapy in Fabry disease in Poland: a position statement","volume":"130","author":"Nowicki","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European Expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3760\/cma.j.issn.0376-2491.2015.23.009","article-title":"Clinical characteristics of multi-organ involvement in patients with Fabry disease","volume":"95","author":"Zhang","year":"2015","journal-title":"Natl. Med. J. China"},{"key":"B4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view.","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3760\/cma.j.cn112148-20231008-00263","article-title":"Chinese expert consensus on the diagnosis and treatment of Fabry disease cardiomyopathy in adults","volume":"52","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1000-3614.2023.01.001","article-title":"2023 Chinese guideline for the diagnosis and treatment of adult hypertrophic cardiomyopathy.","volume":"38","year":"2023","journal-title":"Chin Circ J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/000348948909800509","article-title":"Otologic histopathology of Fabry's disease.","volume":"98","author":"Schachern","year":"1989","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","article-title":"Hot topics in Fabry disease.","volume":"94","author":"Cairns","year":"2018","journal-title":"Postgrad Med J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1536114","DOI":"10.3389\/fcvm.2025.1536114","article-title":"Females with Fabry disease: an expert opinion on diagnosis, clinical management, current challenges and unmet needs.","volume":"12","author":"Tuttolomondo","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107786","DOI":"10.1016\/j.carpath.2025.107786","article-title":"Pathological capillary analysis of ischemia with non-obstructive coronary arteries in a Fabry disease patient receiving enzyme replacement therapy.","volume":"80","author":"Kanamori","year":"2025","journal-title":"Cardiovasc Pathol"},{"key":"B12","first-page":"1347","article-title":"Canadian Fabry disease treatment guidelines 2018.","volume":"35","author":"Sirrs","year":"2019","journal-title":"Can J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/jhg.2012.32","article-title":"New mutations in the GLA gene in Brazilian families with Fabry disease.","volume":"57","author":"Turaca","year":"2012","journal-title":"J Hum Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank.","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J Med Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry disease via analysis of family history.","volume":"17","author":"Laney","year":"2008","journal-title":"J Genet Couns"},{"key":"B17","first-page":"51","article-title":"A family with Fabry disease: case report and literature review.","volume":"14","author":"Ji","year":"2015","journal-title":"J Diagn Concepts Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"s10","DOI":"10.1590\/1806-9282.66.s1.10","article-title":"Fabry disease: genetics, pathology, and treatment.","volume":"66","author":"Bernardes","year":"","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.2174\/1381612826666200317142412","article-title":"Treatment of Anderson-Fabry disease.","volume":"26","author":"Simonetta","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3760\/cma.j.cn112138-20201218-01028","article-title":"Chinese expert consensus on the diagnosis and treatment of Fabry disease (2021 edition)","volume":"60","year":"2021","journal-title":"Chin J Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1846913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:31Z","timestamp":1781760631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1846913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2026.1846913"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1846913","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1846913"}}